sobycor õhukese polümeerikattega tablett
krka d.d. novo mesto - bisoprolool - õhukese polümeerikattega tablett - 2,5mg 56tk; 2,5mg 90tk; 2,5mg 20tk; 2,5mg 50tk; 2,5mg 84tk; 2,5mg 60tk; 2,5mg 10tk; 2,5mg 30tk; 2,5mg 100tk; 2,5mg 28tk
sobycor õhukese polümeerikattega tablett
krka d.d. novo mesto - bisoprolool - õhukese polümeerikattega tablett - 10mg 60tk; 10mg 30tk; 10mg 90tk; 10mg 100tk; 10mg 84tk; 10mg 28tk; 10mg 56tk; 10mg 10tk; 10mg 50tk; 10mg 20tk
sobycor õhukese polümeerikattega tablett
krka d.d. novo mesto - bisoprolool - õhukese polümeerikattega tablett - 5mg 50tk; 5mg 30tk; 5mg 10tk; 5mg 84tk; 5mg 60tk; 5mg 20tk; 5mg 28tk; 5mg 90tk; 5mg 100tk; 5mg 56tk
sobycombi tablett
krka, d.d., novo mesto - bisoprolool+amlodipiin - tablett - 5mg+10mg 30tk; 5mg+10mg 28tk; 5mg+10mg 84tk; 5mg+10mg 56tk; 5mg+10mg 90tk; 5mg+10mg 60tk
sobycombi tablett
krka, d.d., novo mesto - bisoprolool+amlodipiin - tablett - 10mg+5mg 30tk; 10mg+5mg 28tk; 10mg+5mg 60tk; 10mg+5mg 90tk; 10mg+5mg 56tk; 10mg+5mg 84tk
sobycombi tablett
krka, d.d., novo mesto - bisoprolool+amlodipiin - tablett - 5mg+5mg 30tk; 5mg+5mg 84tk; 5mg+5mg 56tk; 5mg+5mg 90tk; 5mg+5mg 28tk; 5mg+5mg 60tk
sobycombi tablett
krka, d.d., novo mesto - bisoprolool+amlodipiin - tablett - 10mg+10mg 84tk; 10mg+10mg 60tk; 10mg+10mg 90tk; 10mg+10mg 30tk; 10mg+10mg 28tk; 10mg+10mg 56tk
rupafin tablett
noucor health s.a. - rupatadiin - tablett - 10mg 3tk; 10mg 50tk; 10mg 7tk; 10mg 15tk; 10mg 20tk; 10mg 30tk; 10mg 10tk; 10mg 100tk
rupafin suukaudne lahus
noucor health s.a. - rupatadiin - suukaudne lahus - 1mg 1ml 120ml 1tk
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol - astma - ravimid hingamisteede obstruktiivsete haiguste, - budesonide / formoterol teva pharma b. on näidustatud ainult 18-aastastel ja vanematel täiskasvanutel. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.